Cure My Disease

Don't miss your cure!

 Log in / Sign up

No new drug, just data: italian study tracks Real-World myeloma care

NCT ID NCT05742217

Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 10, 2026 · Updated 3 times

Summary

This study is not testing a new treatment. Instead, researchers in Italy are observing how doctors currently treat a tough form of multiple myeloma that no longer responds to three main drug classes. They will collect information from medical records of about 250 patients across 25 centers to understand which treatments are used and how well they work in everyday practice. No extra visits or tests are required for participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

121 people

The number who actually took part.

Started

May 2023

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients must have evidence of the following criteria in their medical records at the date of first dose of first treatment after TCR MM eligibility to be included in this study:

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Diagnosis of MM confirmed using International Myeloma Working Group (IMWG) criteria * Patients are TCR defined as being refractory to all the 3 following classes: at least 1IMiD, at least 1PI and at least 1 anti-CD38 mA * Relapsed/refractory to last anti-MM regimen prior to first treatment after TCR * Started anti-MM treatment after TCR MM eligibility * Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (at the date of first dose of first treatment after TCR MM eligibility, or no longer than 6 months prior to this date) * Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. Signed Patient informed consent and Privacy consent documents Exclusion Criteria: * Suffering from Smoldering MM * Suffering from Plasma cell leukemia * Suffering from amyloidosis * Suffering from active Graft versus host disease (GvHD) * Suffering from any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer or carcinoma in situ * Patients whose first treatment after becoming TCR was part of a clinical trial * Participation in Elranatamab EAP

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Refractory multiple myeloma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Refractory multiple myeloma Relapse multiple myeloma

Contacts and locations

Locations

  • "IRCCS "" Casa Sollievo della Sofferenza""tOpera di San Pio da Pietrelcina U.O.C di Ematologia"

    San Giovanni Rotondo, Foggia, 71013, Italy

  • A.O.O.R. Villa Sofia Cervello, U.O. Oncoematologia

    Palermo, Sicily, 90146, Italy

  • A.O.U Policlinico G. Rodolico S. Marco

    Catania, Sicily, 95123, Italy

  • A.O.U. - Ospedali Riuniti di Ancona

    Torrette, Aviano, 60126, Italy

  • A.O.U. Policlinico Paolo Giaccone

    Palermo, Sicily, 90129, Italy

  • A.O.U. Policlinico S.Orsola Malpighi

    Bologna, BO, 40138, Italy

  • A.O.U. Policlinico Università degli Studi di Napoli "Federico II"

    Naples, 80131, Italy

  • AOU Policlinico Umberto I

    Rome, Lazio, 00161, Italy

  • AUSL della Romagna P.O. Ospedale Infermi U.O. di Oncologia

    Rimini, 47923, Italy

  • Arcispedale Santa Maria Nuova

    Reggio Emilia, 42123, Italy

  • Azienda Ospedaliera Universitaria Careggi

    Florence, 50134, Italy

  • Azienda Ospedaliero - Universitaria Di Parma

    Parma, 43126, Italy

  • Azienda Ospedaliero-Universitaria Maggiore della Carita

    Novara, 28100, Italy

  • Busto Arsizio Hospital

    Varese, 21052, Italy

  • Clinica di Oncologia Medica Policlinico San Martino

    Genova, 16132, Italy

  • Fondazione IRCCS Policlinico Sa Matteo U.O.C. Ematologia

    Pavia, Lombardy, 27100, Italy

  • IRST, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

    Meldola (FC), 47014, Italy

  • Irccs Crob

    Rionero in Vulture, 85028, Italy

  • Ospedale Civile dello Spirito Santo

    Pescara, 65124, Italy

  • San Giovanni Di Dio E Ruggi D'Aragona Hospital

    Salerno, 84131, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.